.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Citi
Argus Health
Cantor Fitzgerald
Mallinckrodt
Farmers Insurance
Fish and Richardson
Deloitte
Chinese Patent Office
McKesson

Generated: December 18, 2017

DrugPatentWatch Database Preview

Teva Branded Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA BRANDED PHARM, and what generic alternatives to TEVA BRANDED PHARM drugs are available?

TEVA BRANDED PHARM has twenty-five approved drugs.

There are forty-six US patents protecting TEVA BRANDED PHARM drugs.

There are five hundred and seventy-eight patent family members on TEVA BRANDED PHARM drugs in thirty-seven countries and thirteen supplementary protection certificates in nine countries.

Summary for Teva Branded Pharm

International Patents:578
US Patents:46
Tradenames:24
Ingredients:14
NDAs:25
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Branded PharmZECUITYsumatriptan succinateSYSTEM;IONTOPHORESIS202278-001Jan 17, 2013DISCNYesNo► Subscribe► Subscribe► Subscribe
Teva Branded PharmSEASONALEethinyl estradiol; levonorgestrelTABLET;ORAL021544-001Sep 5, 2003ABRXYesYes► Subscribe► Subscribe► Subscribe
Teva Branded PharmZECUITYsumatriptan succinateSYSTEM;IONTOPHORESIS202278-001Jan 17, 2013DISCNYesNo► Subscribe► SubscribeY► Subscribe
Teva Branded PharmZIACbisoprolol fumarate; hydrochlorothiazideTABLET;ORAL020186-001Mar 26, 1993ABRXYesNo► Subscribe► Subscribe► Subscribe
Teva Branded PharmPROAIR RESPICLICKalbuterol sulfatePOWDER, METERED;INHALATION205636-001Mar 31, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
Teva Branded PharmENJUVIAestrogens, conjugated synthetic bTABLET;ORAL021443-003May 10, 2004DISCNNoNo► Subscribe► SubscribeYY► Subscribe
Teva Branded PharmPROAIR RESPICLICKalbuterol sulfatePOWDER, METERED;INHALATION205636-001Mar 31, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
Teva Branded PharmAUSTEDOdeutetrabenazineTABLET;ORAL208082-001Apr 3, 2017RXYesNo► Subscribe► SubscribeYY► Subscribe
Teva Branded PharmLOSEASONIQUEethinyl estradiol; levonorgestrelTABLET;ORAL022262-001Oct 24, 2008ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Branded PharmAUSTEDOdeutetrabenazineTABLET;ORAL208082-002Apr 3, 2017RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Teva Branded Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Branded PharmZIACbisoprolol fumarate; hydrochlorothiazideTABLET;ORAL020186-003Mar 26, 1993► Subscribe► Subscribe
Teva Branded PharmQVAR 80beclomethasone dipropionateAEROSOL, METERED;INHALATION020911-001Sep 15, 2000► Subscribe► Subscribe
Teva Branded PharmNORDETTE-21ethinyl estradiol; levonorgestrelTABLET;ORAL-21018668-001May 10, 1982► Subscribe► Subscribe
Teva Branded PharmQVAR 40beclomethasone dipropionateAEROSOL, METERED;INHALATION020911-002Sep 15, 2000► Subscribe► Subscribe
Teva Branded PharmQVAR 40beclomethasone dipropionateAEROSOL, METERED;INHALATION020911-002Sep 15, 2000► Subscribe► Subscribe
Teva Branded PharmCENESTINestrogens, conjugated synthetic aTABLET;ORAL020992-004Mar 13, 2000► Subscribe► Subscribe
Teva Branded PharmCENESTINestrogens, conjugated synthetic aTABLET;ORAL020992-002Mar 24, 1999► Subscribe► Subscribe
Teva Branded PharmQNASLbeclomethasone dipropionateAEROSOL, METERED;NASAL202813-002Dec 17, 2014► Subscribe► Subscribe
Teva Branded PharmNORDETTE-21ethinyl estradiol; levonorgestrelTABLET;ORAL-21018668-001May 10, 1982► Subscribe► Subscribe
Teva Branded PharmSEASONALEethinyl estradiol; levonorgestrelTABLET;ORAL021544-001Sep 5, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for TEVA BRANDED PHARM drugs

Drugname Dosage Strength Tradename Submissiondate
levonorgestrel; ethinyl estradiol;ethinyl estradiolTablets0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mgQUARTETTE7/10/2013
levonorgestrel;ethinyl estradiol;ethinyl estradiolTablets0.1 mg/0.02 mg and 0.01 mgLOSEASONIQUE11/16/2009
conjugated estrogen (synthetic a)Tablets0.3 mg, 0.45 mg and 0.9 mgCENESTIN3/19/2009
conjugated estrogen (synthetic a)Tablets0.625 mgCENESTIN3/2/2009
conjugated estrogen (synthetic a)Tablets1.25 mgCENESTIN11/3/2008
levonorgestrel; ethinyl estradiol; ethinyl estradiolTablets0.15 mg/0.03 mg/0.01 mgSEASONIQUE1/22/2008
levonorgestrel and ethinyl estradiolTablets0.15 mg/0.03 mgSEASONALE3/29/2004

Premature patent expirations for TEVA BRANDED PHARM

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Teva Branded Pharm

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,174,013Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
9,808,587Dose counter for inhaler having an anti-reverse rotation actuator► Subscribe
9,526,850Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
8,338,396Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology► Subscribe
7,749,989Estrogenic compounds, methods of using and methods of administering the same► Subscribe
6,250,127 Heat-dissipating aluminum silicon carbide composite manufacturing method► Subscribe
7,772,219Methods of hormonal treatment utilizing extended cycle contraceptive regimens► Subscribe
8,680,084Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology► Subscribe
9,533,111Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
9,526,851Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Teva Branded Pharm Drugs

Country Document Number Estimated Expiration
Israel162182► Subscribe
World Intellectual Property Organization (WIPO)2007120747► Subscribe
Hong Kong1222813► Subscribe
Australia1234297► Subscribe
World Intellectual Property Organization (WIPO)2009154649► Subscribe
Japan5820006► Subscribe
Japan2011173910► Subscribe
Germany60131253► Subscribe
Japan2004529664► Subscribe
Japan4897570► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Teva Branded Pharm Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0814Netherlands► SubscribePRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
1214076/01Switzerland► SubscribePRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
2009 00017Denmark► SubscribePRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
0160011 00192Estonia► SubscribePRODUCT NAME: LEVONORGESTREEL JA ETUENUEUELOESTRADIOOL;REG NO/DATE: EE 894715 11.11.2015
/2015Austria► SubscribePRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
156Luxembourg► SubscribePRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
2006 00038Denmark► SubscribePRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
00221Netherlands► SubscribePRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
C0001France► SubscribePRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
2015000093Germany► SubscribePRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Mallinckrodt
Julphar
US Department of Justice
Argus Health
Deloitte
Merck
Healthtrust
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot